000283062 001__ 283062
000283062 005__ 20260107144733.0
000283062 0247_ $$2doi$$a10.1002/alz70857_105570
000283062 0247_ $$2pmid$$apmid:41445242
000283062 0247_ $$2pmc$$apmc:PMC12739277
000283062 0247_ $$2ISSN$$a1552-5260
000283062 0247_ $$2ISSN$$a1552-5279
000283062 037__ $$aDZNE-2025-01469
000283062 041__ $$aEnglish
000283062 082__ $$a610
000283062 1001_ $$aSannemann, Lena$$b0
000283062 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283062 245__ $$aPredictors of Cognitive Decline in Individuals with Subjective Cognitive Decline of the DELCODE Study Cohort
000283062 260__ $$c2025
000283062 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767013379_31206
000283062 3367_ $$033$$2EndNote$$aConference Paper
000283062 3367_ $$2BibTeX$$aINPROCEEDINGS
000283062 3367_ $$2DRIVER$$aconferenceObject
000283062 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283062 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283062 3367_ $$2ORCID$$aOTHER
000283062 520__ $$aSubjective cognitive decline (SCD) refers to a self-perceived, persistent cognitive decline compared to previous levels in individuals with objectively unimpaired cognition. Studies have repeatedly shown associations of SCD characteristics with amyloid pathology and increased risk of future cognitive decline, especially in memory-clinic settings. The aim of this project is to model individual differences of cognitive decline in individuals with SCD.Latent Growth Curve Model (LGCM) analysis was applied to individuals with SCD from the DZNE Longitudinal Cognitive Impairment and Dementia (DELCODE) study. We chose a sample of n = 203 participants who showed a decline on the Preclinical Alzheimer's Cognitive Composite (PACC5) score over five years. First, a two-factor linear growth model was fitted on the annualized PACC5 data. We then calculated and compared two models to which we added the following baseline predictors: 1) plasma Aß42/40, plasma ptau181, ApoE-4-carrier status and hippocampal volume (biological model), and 2) Geriatric Depression Scale (GDS), Geriatric Anxiety Inventory-Short Form (GAIS-SF) and Neuropsychiatric Inventory Questionnaire (NPI-Q) total scores (neuropsychiatric model).The LGCM of longitudinal PACC-5 scores yielded adequate model fit for a linear model (X2(16)=67.5, p < .001, CFI = 0.93, SMRM=0.07, AIC=1437.10). The baseline PACC score was -0.03 (SE = 0.05, p = .533) and average cognition declined slightly over time by -0.13 (SE = 0.01, p < .001). The biological model showed an improvement in fit, with an AIC of 742.30. Here, we observed a positive relationship between plasma Aß42/40 and the intercept (B = 7.60, SE = 3.01, p = .012) and a negative relationship between plasma ptau181 and the intercept (B = -0.22, SE = 0.09, p = .016). Plasma Aß42/40 was the only significant predictor of the PACC5 slope in this model (B = 1.35, SE = 0.62, p = .030). In comparison, the AIC value for the neuropsychiatric model was 1341.17, with the GDS total score being negatively related to the PACC5 slope (B = -0.03, SE = 0.01, p = .009).These results add to gaining a better understanding of SCD trajectories and specific predictors of cognitive decline, which is relevant to power future clinical trials in this population.
000283062 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283062 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283062 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000283062 650_7 $$2NLM Chemicals$$atau Proteins
000283062 650_7 $$2NLM Chemicals$$aPeptide Fragments
000283062 650_7 $$2NLM Chemicals$$aApolipoprotein E4
000283062 650_2 $$2MeSH$$aHumans
000283062 650_2 $$2MeSH$$aMale
000283062 650_2 $$2MeSH$$aFemale
000283062 650_2 $$2MeSH$$aCognitive Dysfunction: blood
000283062 650_2 $$2MeSH$$aCognitive Dysfunction: pathology
000283062 650_2 $$2MeSH$$aCognitive Dysfunction: psychology
000283062 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000283062 650_2 $$2MeSH$$aCognitive Dysfunction: genetics
000283062 650_2 $$2MeSH$$aAged
000283062 650_2 $$2MeSH$$aAmyloid beta-Peptides: blood
000283062 650_2 $$2MeSH$$atau Proteins: blood
000283062 650_2 $$2MeSH$$aNeuropsychological Tests: statistics & numerical data
000283062 650_2 $$2MeSH$$aLongitudinal Studies
000283062 650_2 $$2MeSH$$aHippocampus: pathology
000283062 650_2 $$2MeSH$$aAlzheimer Disease
000283062 650_2 $$2MeSH$$aMiddle Aged
000283062 650_2 $$2MeSH$$aPeptide Fragments: blood
000283062 650_2 $$2MeSH$$aAged, 80 and over
000283062 650_2 $$2MeSH$$aApolipoprotein E4: genetics
000283062 693__ $$0EXP:(DE-2719)DELCODE-20140101$$5EXP:(DE-2719)DELCODE-20140101$$eLongitudinal Cognitive Impairment and Dementia Study$$x0
000283062 7001_ $$0P:(DE-2719)2811351$$aBuerger, Katharina$$b1$$udzne
000283062 7001_ $$0P:(DE-2719)9003016$$aHellmann-Regen, Julian$$b2$$udzne
000283062 7001_ $$0P:(DE-2719)2812139$$aKleineidam, Luca$$b3$$udzne
000283062 7001_ $$0P:(DE-2719)2000055$$aLaske, Christoph$$b4$$udzne
000283062 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b5$$udzne
000283062 7001_ $$0P:(DE-2719)2811024$$aPeters, Oliver$$b6$$udzne
000283062 7001_ $$0P:(DE-2719)2811122$$aPriller, Josef$$b7$$udzne
000283062 7001_ $$0P:(DE-2719)2812825$$aRamirez, Alfredo$$b8$$udzne
000283062 7001_ $$0P:(DE-2719)2812035$$aSchneider, Anja$$b9$$udzne
000283062 7001_ $$0P:(DE-2719)2811324$$aSpottke, Annika$$b10$$udzne
000283062 7001_ $$0P:(DE-2719)2811275$$aSynofzik, Matthis$$b11$$udzne
000283062 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan J$$b12$$udzne
000283062 7001_ $$0P:(DE-2719)2000057$$aWagner, Michael$$b13$$udzne
000283062 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b14$$udzne
000283062 7001_ $$0P:(DE-2719)2812398$$aYakupov, Renat$$b15$$udzne
000283062 7001_ $$0P:(DE-2719)2000005$$aDüzel, Emrah$$b16$$udzne
000283062 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b17$$eLast author$$udzne
000283062 7001_ $$aGroup, DELCODE Study$$b18$$eCollaboration Author
000283062 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70857_105570$$gVol. 21 Suppl 3, no. Suppl 3, p. e105570$$nSuppl 3$$pe105570$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283062 8564_ $$uhttps://pub.dzne.de/record/283062/files/DZNE-2025-1469.pdf$$yOpenAccess
000283062 8564_ $$uhttps://pub.dzne.de/record/283062/files/DZNE-2025-1469.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283062 909CO $$ooai:pub.dzne.de:283062$$pVDB
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811351$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003016$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812139$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000055$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811024$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811122$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812825$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812035$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811324$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811275$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000057$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812398$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b15$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000283062 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b17$$kDZNE
000283062 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283062 9141_ $$y2025
000283062 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283062 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283062 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283062 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283062 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283062 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283062 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283062 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283062 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283062 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283062 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x0
000283062 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x1
000283062 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x2
000283062 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lInterdisciplinary Dementia Research$$x3
000283062 9201_ $$0I:(DE-2719)1011201$$kAG Wagner$$lNeuropsychology$$x4
000283062 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x5
000283062 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x6
000283062 9201_ $$0I:(DE-2719)5000000$$kAG Peters$$lBiomarker-Assisted Early Detection of Dementias$$x7
000283062 9201_ $$0I:(DE-2719)5000007$$kAG Priller$$lTranslational Neuropsychiatry$$x8
000283062 9201_ $$0I:(DE-2719)1011101$$kPatient Studies (Bonn)$$lPatient Studies (Bonn)$$x9
000283062 9201_ $$0I:(DE-2719)1011103$$kAG Spottke$$lClinical Research Platform (CRP)$$x10
000283062 9201_ $$0I:(DE-2719)1011305$$kAG Schneider$$lTranslational Dementia Research (Bonn)$$x11
000283062 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x12
000283062 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x13
000283062 980__ $$aabstract
000283062 980__ $$aVDB
000283062 980__ $$ajournal
000283062 980__ $$aI:(DE-2719)1011102
000283062 980__ $$aI:(DE-2719)5000006
000283062 980__ $$aI:(DE-2719)1111015
000283062 980__ $$aI:(DE-2719)1811005
000283062 980__ $$aI:(DE-2719)1011201
000283062 980__ $$aI:(DE-2719)1210000
000283062 980__ $$aI:(DE-2719)5000022
000283062 980__ $$aI:(DE-2719)5000000
000283062 980__ $$aI:(DE-2719)5000007
000283062 980__ $$aI:(DE-2719)1011101
000283062 980__ $$aI:(DE-2719)1011103
000283062 980__ $$aI:(DE-2719)1011305
000283062 980__ $$aI:(DE-2719)1510100
000283062 980__ $$aI:(DE-2719)1410006
000283062 980__ $$aUNRESTRICTED